July to September

• Net sales amounted to MSEK 0 (0)

• Net loss was MSEK -5.3 (-6.1), corresponding to earnings per share of SEK -0.09 (-0.11)

• Cash flow after financing activities amounted to MSEK -6.1 (+39.1)

• Cash amounted to MSEK 23.5 (52.1), compared to MSEK 45.3 on 31 December 2021

January to September

• Net sales amounted to MSEK 0 (0)

• Net loss was MSEK -19.9 (-21.1), corresponding to earnings per share of SEK -0.33 (-0.49)

• Cash flow after financing activities amounted to MSEK -21.8 (-27.9)

Significant events during January – September

• In January 2022, warrants corresponding to a dilution of 0.2% of the number of outstanding shares were deregistered.

• In February 2022, the first trial person was enrolled in PHSU05 (ensereptide).

• The recruitment target for the study was achieved according to plan in March.

• At the AGM in May, Marianne Dicander Alexandersson was elected new chairman of the board. Also, Candice Jung was elected new member of the board.

• In September 2022, the last clinic visit in PHSU05 occurred (ensereptide).

• In August 2022, the company received a granted patent in the European Union for the use of the candidate drug ropo-camptide (LL-37) for the treatment of chronic wounds.

Events after the reporting period

• In November 2022, it was announced that results from PHSU05 are expected in April 2023, where the lack of special-ized staff and equipment is the reason for the slight delay

” The third quarter of the year has been characterized by continued progress within our two clinical development programs”

Jonas Ekblom, President and CEO of Promore Pharma